Non-aqueous liquid nimodipine compositions
Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein.
1. A composition comprising nimodipine as the only active ingredient and one or more solvents selected from ethanol, polyethylene glycol, and glycerin, wherein about 5% or less nimodipine degradation is observed over a period of at least six months when exposed to 40° C. and 75% relative humidity, and the concentration of nimodipine in the composition is about 6 mg/mL.
2. The composition of claim 1 , further comprising from about 0.01% to about 1.5% nimodipine related compound A.
3. The composition of claim 1 , wherein nimodipine is present in an amount from about 10 mg to about 100 mg per dosage unit.
4. The composition of claim 1 , wherein nimodipine is present in an amount of about 60 mg per dosage unit.
5. A method of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms comprising enterally administering to a patient in need thereof an effective amount of the composition of claim 1 .
6. The method of claim 5 , wherein the composition is administered orally, via nasogastric tube or via gastric tube.
7. The method of claim 5 , wherein a first unit dose of the composition is administered to the patient within about 100 hours of the subarachnoid hemorrhage.
8. The method of claim 5 , wherein the composition is administered about every four hours.